Efficacy of sorafenib in advanced differentiated and medullary thyroid cancer: experience in a Turkish population

BENEKLİ, MUSTAFA; YALÇIN, ŞUAYİB; ÖZKAN, METİN; ELKIRAN, EMİN; Sevinc, Alper; ÇABUK, DEVRİM; COŞKUN, HASAN; Oksuzoglu, Berna; Bayar, Banu; Akbulat, Akif; Ozet, Ahmet

doi:10.2147/ott.s70670

Efficacy of sorafenib in advanced differentiated and medullary thyroid cancer: experience in a Turkish population

BENEKLİ M., YALÇIN Ş., ÖZKAN M., ELKIRAN E. T., Sevinc A., ÇABUK D., ...More

ONCOTARGETS AND THERAPY, vol.8, pp.1-5, 2015 (SCI-Expanded, Scopus)

Publication Type: Article / Article
Volume: 8
Publication Date: 2015
Doi Number: 10.2147/ott.s70670
Journal Name: ONCOTARGETS AND THERAPY
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Page Numbers: pp.1-5
Open Archive Collection: AVESIS Open Access Collection
Hacettepe University Affiliated: Yes

Abstract

Background: Antivascular endothelial growth factor tyrosine kinase inhibitors have been used recently in the treatment of advanced differentiated thyroid cancer (DTC) and medullary thyroid cancer (MTC). Off-label sorafenib is used in Turkey with special permission by the Ministry of Health for this indication.